Skip to main content

Table 1 Baseline and End of Study Anthropometric and Metabolic Measures in Controls and Cases

From: Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study

 

Baseline

P+

End of the Study

P+

A vs. C‡

B vs. D‡

 

Control (A) n = 15

Case (B) n = 17

 

Control (C) n = 15

Case (D) n = 17

   

Age, y §

21.5 ± 2.19

20.3 ± 1.44

0.08

72.40 (65.66 – 82.08)

76.30 (69.90 – 82.22)

0.39

0.80

0.0003*

Weight, kg.

72.20 (66.55 – 80.75)

81.10 (72.08–84.7)

0.06

     

Height, cm

157 (151.26 – 163.47)

161 (156 - 164)

0.24

     

BMI kg/m2

28.89 (27.78 – 31.12)

30.50 (28.50 – 32. 69)

0.15

29.10 (27.73. 30.88)

28.80 (27.50 – 30.78)

0.74

0.76

0.0002*

FM kg

26.7 (23.15 – 31.26)

32.6 (23.51 – 34.4)

0.08

27.60 (23.50 – 31.01)

29.40 (23.12 – 33.07)

0.67

0.58

0.0005*

FFM kg

45.70 (42.13 – 48.26)

48.70 (46.20 – 50.29)

0.08

44.80 (41.75 – 47.94)

47.90 (45.80 – 49.39)

0.06

0.13

0.03*

Waist cm

83 (80.38 – 88)

86.40 (82.02 – 91.98)

0.24

82.50 (79.76 – 86.15)

83 (79.50 – 86)

0.74

0.11

< 0.0001*

Hip cm

108 (102.26 – 110.62)

112.5 (105.04 – 115.46)

0.07

106.5 (102.52 – 108.73)

108 (103 – 111)

0.76

0.54

0.0002*

Waist to Hip Ratio

0.79 (0.76 - 0.81)

0.78 (0.77 - 0.81)

0.80

0.77 (0.75 - 0.80)

0.78 (0.75 - 0.79)

0.63

0.27

0.04*

Adiponectin ug/ml

11.54 (7.88 – 15.26)

11.72 (7.29 – 15.06)

0.61

12.33 (8.36 – 15.60)

15.76 (9.96 – 23.44)

0.32

0.80

< 0.0001*

Leptin ng/ml

30.33 (25.30 – 36.06)

28.31 (23.82 – 35.12)

0.71

29.42 (21.51 – 37)

18.13 (12.94 – 24.31)

0.002*

0.45

0.03*

TNFa pg/ml

4.44 (4.10 – 6.14)

4.33 (2.90 – 5.31)

0.25

5.05 (4.12 – 6.76)

4.10 (3.53 – 4.98)

0.036*

0.12

0.93

Insulin, mg/dl

13.72 (11.47 – 24.95)

12.01 (8.64–16.74)

0.14

12.73 (10.70 – 19.43)

12.89 (6.42 – 14.37)

0.12

0.01*

0.17

Glucose, mg/dl

84 (80.26 – 88)

74 (73–78.96)

0.003*

86 (82.26 – 87)

82 (76.01 – 87)

0.39

0.80

0.05*

CHOL, mg/dl

78 (59.05 – 149.02)

78 (62.03 – 111.79)

0.69

78 (65.79 – 113)

66 (59.03 – 99-95)

0.15

0.59

0.33

TGL mg/dl

160 (144.52 – 182.41)

153 (144.04 – 186.98)

0.87

165 (149.70 – 186.73)

168 (152.01 – 184. 91)

0.79

0.42

0.12

HDL mg/dl

49 (36.26 – 54.94)

45 (41.01 – 71.74)

0.39

45 (39.26 – 53.47)

44 (40 – 55.93)

0.98

0.84

0.32

LDL mg/dl

104 (98–109.47)

105 (102.01 – 109.98)

0.50

95 (90 – 102.41)

92 (80.12 – 97.98)

0.36

0.20

0.0001*

HOMA

2.88 (2.29 – 5.20)

2.22 (1.59 – 3.01)

0.047*

2.58 (2.29 – 4.20)

2.29 (1.47 – 2.83)

0.15

0.06

0.40

FFA mEq/L

0.40 (0.30 - 0.50)

0.40 (0.30 - 0.59)

0.39

0.50 (0.32 - 0.60)

0.40 (0.40 - 0.60)

0.86

0.27

0.23

  1. ^ Results are reported in median and 95% Confidence Interval, except age (§), which is mean ± SD.
  2. FFA denotes Free-fat Mass, FM fat mass, BMI body mass index, W/H Waist to Hip Ratio, TNFa tumor necrosis factor alpha, CHOL Cholesterol, TGL Triglycerides, HOMA Homeostatic Model Assessment, HDL high-density lipoprotein, LDL low-density lipoprotein, FFA Free fatty acids.
  3. +p Values where calculated by Mann–Whitney Test.
  4. ‡p Values where calculated by Wilcoxon Rank Test.
  5. * Significant Result p < 0.05.
Back to article page

Journal of the International Society of Sports Nutrition

ISSN: 1550-2783

Contact us